TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24058684
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg.kg(‐1) of body weight)
Study: 15307698
Drug: Xiaoyan Zhixue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyan Zhixue Capsule (XYZXC)
Study: 9259359
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride pills (60 mEq of sodium per day)
Study: 8481365
Drug: Doxorubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (70 mg/m2)
Study: 8481365
Drug: Epirubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (70 mg/m2)
Study: 8481365
Drug: Mitozantrone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone (14 mg/m2)
Study: 3102153
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat
Study: 3102153
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein
Study: 3102153
Drug: Insulin‐induced hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐induced hypoglycaemia
Study: 3102153
Drug: Intravenous arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous arginine
Study: 3102153
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate
Study: 28888220
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg immediate-release co-crystal of tramadol-celecoxib (CTC)
Study: 28888220
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg immediate-release tramadol
Study: 28888220
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg immediate-release tramadol and 100 mg celecoxib
Study: 16308443
Drug: Plaferon LB
Normalized name: LB-100
DrugBank: LB-100 (DB15412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaferon LB (5 mg/ml - 3 ml daily inhalations)
Study: 16308443
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert solution)
Study: 12531809
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg/m(2)/d for 28 days in induction, plus taper)
Study: 12531809
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/m(2)/d)
Study: 12531809
Drug: Oral 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 6-mercaptopurine
Study: 14610016
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (no abciximab)
Study: 9440388
Drug: High-RS diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-RS diet (amylomaize starch, 55.2 +/- 3.5 g RS/d)
Study: 9440388
Drug: Low-RS diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-RS diet (available cornstarch, 7.7 +/- 0.3 g RS/d)
Study: 8591965
Drug: Prenephrectomy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenephrectomy therapy
Study: 23455033
Drug: Abciximab and
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab and heparin
Study: 19587440
Drug: Tongxinluo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo (4 capsules once, 3 times per day)
Study: 11778566
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) at a dose of 25.2‐30.6 Gy
Study: 28528536
Drug: R+D (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: R+D (10 mL of 0.25% ropivacaine + 0.5μg/kg dexmedetomidine)
Study: 28528536
Drug: R (10
Normalized name: Avar (10 % / 5 % ) Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: R (10 mL of 0.25% ropivacaine)
Study: 27224446
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin (ASA) 100mg per day
Study: 27224446
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (ASA) 100mg per day via gastric tube
Study: 27224446
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response to aspirin (both IV and oral)
Study: 25222173
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in Perceived Vulnerability (PV) from baseline to end of treatment
Study: 10390223
Drug: Amprenavir (141W94)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (141W94) 150 mg
Study: 10390223
Drug: Amprenavir (141W94)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (141W94) 300 mg
Study: 10390223
Drug: Amprenavir (141W94)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (141W94) 600 mg
Study: 10390223
Drug: Amprenavir (141W94)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (141W94) 900 mg
Study: 10390223
Drug: Amprenavir (141W94)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (141W94) 1200 mg
Study: 10390223
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule of amprenavir
Study: 25276591
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin administered by traditional birth attendants (TBAs)
Study: 25276591
Drug: Referral and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral and/or initiation of antibiotics
Study: 11974558
Drug: 17 beta-estradiol/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol/levonorgestrel 50/10 micrograms/24 h patch
Study: 11974558
Drug: 17 beta-estradiol/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol/levonorgestrel 75/15 micrograms/24 h patch
Study: 11974558
Drug: 17 beta-estradiol/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol/levonorgestrel 100/20 micrograms/24 h patch
Study: 9784666
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment in iron-depleted patients
Study: 9784666
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy in iron-replete patients
Study: 7572595
Drug: Diltiazem controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem controlled diffusion (CD) 300 mg
Study: 2258341
Drug: Pefloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (800 mg single dose)
Study: 2258341
Drug: Co-trimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (960 mg twice daily for 5 days)
Study: 7273010
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen of PALA and 5-FU (24 patients)
Study: 21422852
Drug: Nutritional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional management with self blood glucose monitoring and insulin as needed
Study: 19272069
Drug: Postoperative low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative low-molecular-weight heparin (LMWH)
Study: 19272069
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative low-molecular-weight heparin (LMWH)
Study: 8791885
Drug: Tretinoin 0.05%
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.05% emollient cream (Retinova ‐ Janssen‐Cilag Ltd)
Study: 1826988
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 10-30 micrograms sufentanil added to 0.125% bupivacaine with epinephrine (1:800,000)
Study: 1826988
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 0.125% bupivacaine with epinephrine (1:800,000) without sufentanil
Study: 28619295
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (one hour a week during four weeks)
Study: 12653169
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zafirlukast b.i.d.
Study: 10529020
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with buprenorphine taper (NB Group)
Study: 10529020
Drug: Buprenorphine taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine taper alone followed by naltrexone (PB Group)
Study: 10529020
Drug: Adjunct medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct medication (clonidine)
Study: 10529020
Drug: Sedatives (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedatives (up to 20 mg diazepam)
Study: 2032147
Drug: Alutard SQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alutard SQ (grass pollen depot preparation)
Study: 6354507
Drug: Mefloquine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1000 mg given in one day)
Study: 6354507
Drug: Chloroquine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (1500 mg given over 3 days)
Study: 27129120
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (20 mg piroxicam capsule)
Study: 27129120
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (20 mg piroxicam capsule)
Study: 20646771
Drug: Honey dressing
Normalized name: MediHoney Dressing 3/4x12"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey dressing applied to wounds for 3 months till healing, grafting or failure of treatment.
Study: 17257466
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (ccHRT) (Indivina)
Study: 17257466
Drug: Lowest dose-combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose-combination of ccHRT
Study: 6230174
Drug: Coumadin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin treatment (prothrombin time 2 to 2.5 times the control value)
Study: 6230174
Drug: Coumadin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin treatment (for patients with at least a 6 month history of angina)
Study: 6230174
Drug: Aspirin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (for patients with at least a 6 month history of angina)
Study: 26306000
Drug: DBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBS plus optimal drug therapy (DBS + ODT)
Study: 27393540
Drug: Isoniazid prophylaxis
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid prophylaxis (exact dosage and duration not specified)
Study: 18755319
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo pills
Study: 17458707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of computer and paper-based CDSS
Study: 15814548
Drug: Tacrolimus (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.2 mg/kg)
Study: 15814548
Drug: Cyclosporin microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin microemulsion (7 mg/kg)
Study: 1832761
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg/day
Study: 11910310
Drug: verapamil 180
Normalized name: verapamil 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 180 + trandolapril 2 mg/day combination
Study: 9426828
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CPA
Study: 9426828
Drug: CPA (10-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA (10-150 mg)
Study: 8131255
Drug: Mefloquine in
Normalized name: Product containing mefloquine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine in combination with artesunate
Study: 8131255
Drug: Artesunate effect
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate effect on mefloquine pharmacokinetics
Study: 31998472
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) consisting of two high-velocity low-amplitude spinal manipulations and two grade IV mobilizations of the lumbar spine and pelvis
Study: 25649543
Drug: Traumeel 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel 2 ml injection
Study: 25649543
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg injection
Study: 19165592
Drug: Child-focused cognitive
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive behavioral therapy (CCBT)
Study: 17890444
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/day for 3 days before MDMA challenge (100 mg oral)
Study: 10485505
Drug: Extended-release etodolac
Normalized name: etodolac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release etodolac 1200 mg
Study: 10485505
Drug: Conventional etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional etodolac 400 mg
Study: 10485505
Drug: Conventional etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional etodolac 200 mg
Study: 1773929
Drug: Hexetidine vaginal
Normalized name: Hexetidine
DrugBank: Hexetidine (DB08958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexetidine vaginal suppositories (10 mg) applied for five days
Study: 1773929
Drug: Hexetidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexetidine (20 mg/day) applied for five days
Study: 1773929
Drug: Hexetidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexetidine (10 mg/day) applied for three days pre-operatively
Study: 1773929
Drug: Hexetidine preparation
Normalized name: Hexetidine
DrugBank: Hexetidine (DB08958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexetidine preparation
Study: 27026043
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day) + Interferon beta-1a (30 micro g/week)
Study: 27026043
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Interferon beta-1a 30 micro g/week)
Study: 19820906
Drug: Radiotherapy in
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy in combination with simultaneous chemotherapy
Study: 19820906
Drug: Postoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative chemoradiation and perioperative chemotherapy
Study: 17255855
Drug: PEEP set
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEEP set at 26 cm H2O and lung recruitment performed (40/40-maneuver) followed by tidal volume set at 4 mL/kg (T26R) and PEEP lowered by 2 cm H2O every 4 mins.
Study: 17255855
Drug: PEEP set
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEEP set at 26 cm H2O and lung recruitment performed (40/40-maneuver) followed by tidal volume set at 6 mL/kg (T(end)).
Study: 11914251
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA 2.5 mg
Study: 11914251
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA 5.0 mg
Study: 11914251
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg)
Study: 9210501
Drug: CsA (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (original formulation)
Study: 3621278
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (two with class IC and two with class IA action)
Study: 31055046
Drug: CALAS 20
Normalized name: CALASPARGASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 20 mg
Study: 31055046
Drug: CALAS 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 40 mg
Study: 31055046
Drug: CALAS 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 80 mg
Study: 31055046
Drug: CALAS 120
Normalized name: verapamil hydrochloride 120 MG [Calan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS 120 mg
Study: 31055046
Drug: CALAS (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALAS (all doses)
Study: 24368613
Drug: Low-dose MBIR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MBIR
Study: 24368613
Drug: Standard-dose FBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FBP
Study: 23070400
Drug: Nabilone 0.5
Normalized name: nabilone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 0.5 mg/day
Study: 10095804
Drug: Folate administration
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate administration (0.25 mg day‐1) plus 60 mg day‐1 of Fe2+
Study: 10095804
Drug: Placebo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (60 mg day‐1 of Fe2+)
Study: 7831065
Drug: TTFCA 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 60 mg
Study: 7831065
Drug: TTFCA 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA 120 mg
Study: 3354874
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg IV
Study: 3354874
Drug: Physostigmine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 2.0 mg IV
Study: 1298332
Drug: Inhaled Bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Bradykinin (8 mg/mL)
Study: 31666084
Drug: umeclidinium/vilanterol 62.5/25
Normalized name: umeclidinium/vilanterol 62.5/25 MCG/INHAL Dry Powder Inhaler, 7 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: umeclidinium/vilanterol 62.5/25 μg once-daily
Study: 31666084
Drug: umeclidinium 62.5
Normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: umeclidinium 62.5 μg once-daily
Study: 31666084
Drug: salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol 50 μg twice-daily
Study: 25896890
Drug: Serum bicarbonate
Normalized name: BICARBONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum bicarbonate >26 mmol/L
Study: 25896890
Drug: Serum bicarbonate
Normalized name: BICARBONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum bicarbonate <22 mmol/L
Study: 25896890
Drug: Serum bicarbonate
Normalized name: BICARBONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum bicarbonate 22 to 26 mmol/L
Study: 19843669
Drug: 1C diet
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1C diet (single dose of cruciferous vegetables)
Study: 19843669
Drug: 2C diet
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2C diet (double dose of cruciferous vegetables)
Study: 19843669
Drug: 1C+A diet
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1C+A diet (single dose of cruciferous and apiaceous vegetables)
Study: 16915511
Drug: Polyglactin/polypropylene compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyglactin/polypropylene compound mesh (group C)
Study: 11734734
Drug: Intranasal trivalent
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal trivalent influenza vaccine (CAIV) - 3 lots (A/Shenzhen/227/95 (H1N1), A/Wuhan/359/95 (H3N2), B/Harbin/7/94-like)
Study: 16551139
Drug: Self-administered behavioral
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered behavioral family intervention
Study: 16551139
Drug: Self-administered behavioral
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered behavioral family intervention plus brief therapist telephone assistance
Study: 12105157
Drug: Aspirin, heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, heparin, and meloxicam
Study: 10202220
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (50/250 microg bid) via a single Diskus inhaler (combination)
Study: 10202220
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg bid via one Diskus inhaler and fluticasone propionate 250 microg bid via another (concurrent)
Study: 7008938
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen of ICRF-159
Study: 31914437
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg intravitreal injections every 4 weeks, adjusted based on CSMT changes
Study: 23294776
Drug: Dulaglutide (dula,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (dula, LY2189265) - a once-weekly glucagon-like peptide-1 analog
Study: 16044027
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg twice daily for 6 months)
Study: 16044027
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg twice daily for 1 month)
Study: 7771102
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with non-steroidal anti-inflammatory drugs (2/3)
Study: 7771102
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with morphine (0/1)
Study: 7771102
Drug: Placebo iontophoresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo iontophoresis (lidocaine, procaine, flufenamic acid, diclofenac, Mobilat, vinca-alkaloids, dexamethasone-lidocaine, morphine, fluoride)
Study: 7771102
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration (procaine, benzocaine-salicylamide, flufenamic acid)